Document:

EX-10.S.1

Exhibit 10(s.1)

AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT

     This Amendment No. 1 to Employment Agreement (“Amendment”) made as of April 10, 2008 between
DUSA Pharmaceuticals, Inc., a New Jersey corporation (“DUSA”) having principal offices at 25 Upton
Drive, Wilmington, Massachusetts 01887, and Scott L. Lundahl. (“Lundahl”), who resides at 4 Morris
Street, Lexington, Massachusetts 02173.

WHEREAS, the parties entered into an Employment Agreement dated June 23, 1999 (the
“Agreement”); and

WHEREAS, the parties now wish to further amend the Agreement in writing to reflect an
increase in the cash bonus opportunity percentage;

NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

1. Paragraph 3 of the Agreement (Remuneration), which reads in relevant part:

Following the end of each fiscal year, the Board may award a cash bonus to Lundahl in an
amount up to 30% of Lundahl’s current base salary for such year as determined by the Board in its
sole discretion.

Shall be amended to reflect an increase in the cash bonus opportunity percentage to read:

Following the end of each fiscal year, the Board may award a cash bonus to Lundahl in an
amount up to 35% of Lundahl’s current base salary for such year as determined by the Board in its
sole discretion.

2. Except as expressly provided in this Amendment No. 1, the Agreement shall remain unmodified and
in full force and effect and is hereby ratified and confirmed. The execution, delivery, and
effectiveness of the Amendment No. 1 shall not, except as expressly provided herein, operate as a
waiver of any right, power, or remedy of Lundahl or DUSA.

     IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 1 to Employment
Agreement as of the latest date and year stated below.

	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	DUSA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent
 

	 	 
	 	By:
	 	/s/ Robert F. Doman
 

	 	 
	 	 	 	 	Robert F. Doman	 	 
	 	 	 	 	President and Chief Executive Officer	 	 
	 

	 	 	 	Dated:
	 	5-13-08	 	 
	 
	 	 	 	 	 	 	 	 
	WITNESS:	 	 	 	EMPLOYEE:	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Joanne LaValle

	 	 	 	 	 	/s/ Scott L. Lundahl	 	 
	 	 	 	 	 	 	 
	 	 	 	 	Scott L. Lundahl	 	 
	 

	 	 	 	Dated:
	 	5-21-08EX-10.T.1

Exhibit 10(t.1)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

     This Amendment No. 2 to Employment Agreement (“Amendment”) made as of April 10, 2008 between
DUSA Pharmaceuticals, Inc., a New Jersey corporation (“DUSA”) having principal offices at 25 Upton
Drive, Wilmington, Massachusetts 01887, and Stuart L. Marcus, M.D., Ph.D., (“Dr. Marcus”), who
resides at 20 Dogwood Road, Mount Kisco, New York 10549

WHEREAS, the parties entered into an Employment Agreement dated October 11, 1993 which was
amended as of December 9, 1999 (the “Agreement”); and

WHEREAS, the parties now wish to further amend the Agreement in writing to reflect an
increase in the cash bonus opportunity percentage;

NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

1. Paragraph 3 of the Agreement (Remuneration), which reads in relevant part:

Following the end of each fiscal year, the Board may award a cash bonus to Dr. Marcus in an
amount up to 30% of Dr. Marcus’ current base salary for such year as determined by the Board in its
sole discretion.

     Shall be amended to reflect an increase in the cash bonus opportunity percentage to read:

Following the end of each fiscal year, the Board may award a cash bonus to Dr. Marcus in an
amount up to 40% of Dr. Marcus’ current base salary for such year as determined by the Board in its
sole discretion.

2. Except as expressly provided in this Amendment No. 2, the Agreement shall remain unmodified and
in full force and effect and is hereby ratified and confirmed. The execution, delivery, and
effectiveness of the Amendment No. 2 shall not, except as expressly provided herein, operate as a
waiver of any right, power, or remedy of Dr. Marcus or DUSA.

     IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 2 to Employment
Agreement as of the latest date and year stated below.

	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	DUSA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent
 

	 	 
	 	By:
	 	/s/ Robert F. Doman
 

Robert F. Doman
	 	 
	 

	 	 	 	 	 	President and Chief Executive Officer	 	 
	 

	 	 	 	Dated:
	 	5-13-08	 	 
	 
	 	 	 	 	 	 	 	 
	WITNESS:	 	 	 	EMPLOYEE:	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent	 	 	 	/s/ Stuart L. Marcus	 	 
	 	 	 	 	 	 	 
	 	 	 	 	Stuart L. Marcus, M.D., Ph.D.	 	 
	 

	 	 	 	Dated:
	 	5/14/08EX-10.U.2

Exhibit 10(u.2)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

     This Amendment No. 2 to Employment Agreement (“Amendment”) made as of April 10, 2008 between
DUSA Pharmaceuticals, Inc., a New Jersey corporation (“DUSA”) having principal offices at 25 Upton
Drive, Wilmington, Massachusetts 01887, and Mark C. Carota (“Carota”), who resides at 144 Old
Westford Road, Chelmsford, Massachusetts 01824.

WHEREAS, the parties entered into an Employment Agreement dated February 14, 2000 which was
amended as of October 31, 2001 (the “Agreement”); and

WHEREAS, the parties now wish to further amend the Agreement in writing to reflect an
increase in the cash bonus opportunity percentage;

NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

1. Paragraph 3 of the Agreement (Remuneration), which reads in relevant part:

Following the end of each fiscal year, the Board may award a cash bonus to Carota in an amount
up to 30% of Carota’s current base salary for such year as determined by the Board in its sole
discretion.

     Shall be amended to reflect an increase in the cash bonus opportunity percentage to read:

Following the end of each fiscal year, the Board may award a cash bonus to Carota in an amount
up to 35% of Carota’s current base salary for such year as determined by the Board in its sole
discretion.

2. Except as expressly provided in this Amendment No. 2, the Agreement shall remain unmodified and
in full force and effect and is hereby ratified and confirmed. The execution, delivery, and
effectiveness of the Amendment No. 2 shall not, except as expressly provided herein, operate as a
waiver of any right, power, or remedy of Carota or DUSA.

     IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 2 to Employment
Agreement as of the latest date and year stated below.

	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	DUSA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent
 

	 	 	 	By:
	 	/s/ Robert F. Doman
 

Robert F. Doman
	 	 
	 

	 	 	 	 	 	President and Chief Executive Officer	 	 
	 

	 	 	 	Dated:
	 	5-13-08	 	 
	 
	 	 	 	 	 	 	 	 
	WITNESS:	 	 	 	EMPLOYEE:	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Marianne Mullin	 	 	 	/s/ Mark C. Carota	 	 
	 	 	 	 	 	 	 
	 	 	 	 	Mark C. Carota	 	 
	 

	 	 	 	Dated:
	 	5-20-08EX-10.W.1

Exhibit 10(w.1)

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT

     This Amendment No. 2 to Employment Agreement (“Amendment”) made as of April 10, 2008 between
DUSA Pharmaceuticals, Inc., a New Jersey corporation (“DUSA”) having principal offices at 25 Upton
Drive, Wilmington, Massachusetts 01887, and Richard C. Christopher (“Christopher”), who resides at
31 Chester Street, Andover, Massachusetts 01810.

WHEREAS, the parties entered into an Employment Agreement dated January 1, 2004 which was
amended as of October 24, 2006 (the “Agreement”); and

WHEREAS, the parties now wish to further amend the Agreement in writing to reflect an
increase in the cash bonus opportunity percentage;

NOW THEREFORE, in consideration of the mutual covenants and promises, the parties agree as
follows:

1. Paragraph 3 of the Agreement (Remuneration), which reads in relevant part:

Following the end of each fiscal year, the Board may award a cash bonus to Christopher in an
amount up to 30% of Christopher’s current base salary for such year as determined by the Board in
its sole discretion.

     Shall be amended to reflect an increase in the cash bonus opportunity percentage to read:

Following the end of each fiscal year, the Board may award a cash bonus to Christopher in an
amount up to 40% of Christopher’s current base salary for such year as determined by the Board in
its sole discretion.

2. Except as expressly provided in this Amendment No. 2, the Agreement shall remain unmodified and
in full force and effect and is hereby ratified and confirmed. The execution, delivery, and
effectiveness of the Amendment No. 2 shall not, except as expressly provided herein, operate as a
waiver of any right, power, or remedy of Christopher or DUSA.

     IN WITNESS WHEREOF, the parties have duly executed this Amendment No. 2 to Employment
Agreement as of the latest date and year stated below.

	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	DUSA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent
 

	 	 
	 	By:
	 	/s/ Robert F. Doman
 

	 	 
	 	 	 	 	Robert F. Doman	 	 
	 	 	 	 	President and Chief Executive Officer	 	 
	 

	 	 	 	Dated:
	 	5-12-08	 	 
	 
	 	 	 	 	 	 	 	 
	WITNESS:	 	 	 	EMPLOYEE:	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent	 	 	 	/s/ Richard C. Christopher	 	 
	 	 	 	 	 	 	 
	 	 	 	 	Richard C. Christopher	 	 
	 

	 	 	 	Dated:
	 	5-12-08EX-10.X.1

Exhibit 10(x.1)

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

BY AND BETWEEN DUSA PHARMACEUTICALS, INC. AND

MR. ROBERT F. DOMAN

     THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this “First Amendment”) is made as of the
26th day of November, 2008 (the “Effective Date”), by and between DUSA Pharmaceuticals,
Inc., a corporation duly organized under the laws of the Commonwealth of Massachusetts, having
offices located at 25 Upton Drive, Wilmington, Massachusetts (“DUSA”), and Robert F. Doman,
currently residing at 30 Monument Square, Suite 410, Charlestown, Massachusetts 02129 (“Doman” and
collectively with DUSA, the “Parties”).

     WHEREAS, DUSA and Doman are parties to that certain employment agreement dated December 29, 2004
(the “Agreement”), pursuant to which DUSA employs Doman as President and Chief Executive Officer
and Doman continues to accept such employment; and

     WHEREAS, Doman’s bonus opportunity was increased at the time of his promotion to Chief Executive
Officer and the parties desire to reflect this change in his Employment Agreement; and

     WHEREAS, DUSA and Doman wish to amend the Agreement to ensure that separation pay that is payable
under the Agreement will not constitute a deferral of compensation under Section 409A of the
Internal Revenue Code of 1986, as amended (the “Code”); and

     NOW, THEREFORE, in consideration of the various promises and undertakings set forth in this
Amendment, the Parties agree to amend the Agreement as follows:

	1.	 	Paragraph 3 of the Agreement (Remuneration), which reads in relevant part:

Following the end of each fiscal year, the Board may award a cash bonus to Doman in
an amount up to Forty percent (40%) of his current base salary for such year, as
determined by the Board in its sold discretion.

     Shall be amended to reflect an increase in the cash bonus opportunity percentage to read:

Following the end of each fiscal year, the Board may award a cash bonus to Doman in
an amount up to Fifty percent (50%) of his current base salary for such year, as
determined by the Board in its sold discretion.

	2.	 	As of the Effective Date, Subsections 10.B.(i) and (iii) of the Agreement are hereby deleted in
their entirety and replaced with the following:

     “10. Termination of Employment.

* * *

          B. If Doman’s employment is terminated by the COMPANY without cause the COMPANY shall:

               (i) pay Doman a severance allowance equivalent to twelve months then current base salary,
payable as a lump sum, within sixty (60) days following the date of such termination;

 

 

* * *

               (iii) Doman will be entitled to continued medical insurance to the same extent in which he
participated prior to his termination date until the earlier to occur of one year following the
termination date or the day Doman becomes eligible for and receives similar benefits with a new
employer. Additionally, Doman will receive, in a lump sum cash payment within sixty (60) days
following his termination, the value of any life insurance or other welfare benefits to the same
extent in which he participated prior to his termination date, as if such benefits were continued
for one year following his termination date.

* * *

     Except as specifically described above, Subsection 10.B. shall remain otherwise unchanged.
Additional text is italicized.

3. As of the Effective Date, the first sentence of Section 11 is hereby deleted in its entirety and
replaced with the following:

     “11. Change of Control. If Doman’s employment agreement is terminated by the COMPANY without
cause upon the consummation of a “change in control” as defined herein or at any time within three
(3) years following such consummation, Doman shall receive, within five (5) days after such
termination (except as otherwise specifically provided below) from the COMPANY or its successor, a
lump sum payment equal to (i) three (3) times his base salary during the last fiscal year in which
Doman is associated with the COMPANY (including any amounts due as severance under Paragraph
10B.(i) of this Agreement) if such termination is made effective on the date of consummation of
such “change of control”, or (ii) three (3) times such base salary (including any amounts due as
severance under Paragraph 10B.(i) of this Agreement) less the amount of salary paid from the date
of consummation to the effective date of termination if such termination is effective following
such consummation but within three years of such consummation; provided, however, Doman shall be
entitled to any amounts due as severance under Paragraph 10B.(i) of this Agreement, immediate
vesting of all stock options, and continued medical benefits to the same extent in which he
participated prior to the change in control until the earlier to occur of one (1) year following
the “change of control” or the date Doman becomes eligible for and receives similar benefits with a
new employer. Additionally, Doman will receive, in a lump sum cash payment within sixty (60) days
following his termination, the value of any life insurance or other welfare benefits to the same
extent in which he participated prior to his termination date, as if such benefits were continued
for one year following his termination date.

     Except as specifically described above, Section 11 shall remain otherwise unchanged.
Additional text is italicized.

4. Effect of Amendment. Except as amended specifically by this First Amendment, the Agreement
shall remain in full force and effect and shall be unaffected by this First Amendment.

5. Defined Terms. All terms used in this First Amendment and not otherwise defined in this First
Amendment shall have the meanings assigned to such terms in the Agreement.

6. Governing Law. This First Amendment shall be governed by the laws of the State of New Jersey.

7. Counterparts. This First Amendment may be executed in counterparts, each of which, when taken
together, shall be deemed to be one and the same instrument.

- 2 -

 

     IN WITNESS WHEREOF, the parties have executed this First Amendment, by their representative
officers hereunto duly authorized, the day and the year first written above.

	 	 	 	 	 	 	 	 	 
	ATTEST:	 	 	 	DUSA PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Patricia Hommel

	 	 	 	By:
	 	/s/ Richard C. Christopher	 	 
	 

	 	 
	 	 	 	 

Richard C. Christopher
	 	 
	 

	 	 	 	 	 	Vice President and Chief Financial Officer	 	 
	 
	 

	 	 	 	Dated:
	 	November 26, 2008	 	 
	 
	 	 	 	 	 	 	 	 
	WITNESS:
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	/s/ Susan Tennent
 

	 	 	 	By:
	 	/s/ Robert F. Doman
 

Robert F. Doman, President and
Chief 
Executive Officer
	 	 
	 
	 

	 	 	 	Dated:
	 	November 26, 2008	 	 

- 3 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]